Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
With an increasing number of similar GLP-1 drugs now being used in clinical practice, for conditions ranging from type 2 diabetes and obesity to kidney disease, our findings highlight the potential for these existing drugs to be repurposed to treat the risk of no-reflow in heart attack patients, offering a potentially life-saving solution, said University College London Professor David Atwell
Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, et al
Relevant for RPE repair and corneal healing
PlexusDx has no commercial relationship with Henry Meds or its parent company, and no affiliate links or compensation are involved
Clinical trial data from the SURMOUNT-5 trial shows tirzepatide produced approximately 47 percent more weight loss than a semaglutide comparator over 72 weeks (average of 50 pounds versus 33 pounds)
